FindTrial
Sign In

STUDY TO ASSESS HEARING LOSS IN PATIENTS RECEIVING SIMULTANEOUS CHEMOTHERAPY AND RADIATION THERAPY FOR HEAD AND NECK CANCERS

STUDY TO ASSESS HEARING LOSS IN PATIENTS RECEIVING CHEMORADIOTHERAPY IN ADJUVANT SETTING FOR HEAD AND NECK MALIGNANCY

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2014/08/004940
Enrollment
50
Registered
2014-08-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- SUFFERING FROM HEAD AND NECK MALIGNANCIES

Interventions

None listed

Sponsors

FATHER MULLER MEDICAL COLLEGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: INDIVIDUALS SUFFERING FROM HEAD AND NECK MALIGNANCIES RECEIVING CHEMO-RADIATION FOR THE SAME WITH TEMPORAL BONE IN THE RADIATION FIELD. INDIVIDUALS WILLING FOR TIMED AUDIOLOGICAL ASSESSMENT.

Exclusion criteria

Exclusion criteria: INDIVIDUALS ALREADY SUFFERING FROM PROFOUND HEARING LOSS AND RECEIVING NEOADJUVANT CHEMORADIOTHERAPY

Design outcomes

Primary

MeasureTime frame
HEARING LOSS IN DECIBELS ACHIEVED BY PURE TONE AUDIOMETRYTimepoint: PRE THERAPY, 3 WEEKS AFTER INITIATING THERAPY, AT THE COMPLETION OF THERAPY, 3 MONTHS FOLLOW UP—

Secondary

MeasureTime frame
DEGREE OF SEVERITY AND TYPE OF HEARING LOSSTimepoint: PRE THERAPY, 3 WEEKS AFTER INITIATING THERAPY, AT THE COMPLETION OF THERAPY, 3 MONTHS FOLLOW UP—

Countries

India

Contacts

Public ContactDR VANI KRISHANA GUPTA

FATHER MULLER MEDICAL COLLEGE

mahesh.t.bhat@gmail.com9886734374

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026